Total revenue for the three months ended Sept. 28 was $367 million compared with $366 million in the same period one year ago. Receipts from the life and ananlytical-sciences unit inched up to $235 million from $232 million during the third quarter 2002, the company said.
Companywide R&D spending was also flat in the third quarter, reaching $20 million from $20.5 million year over year.
However, net income doubled in the current quarter to $14.3 million, or $.11 per share, from $7 million, or $.06 per share, in the same quarter last year.
PerkinElmer said it had around $141 million in cash and cash equivalents as of Sept. 29.